This is a firm fixed-price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to Applied Stemcell, Inc. for $9,027.20. The contract, which has no set-aside designation, was awarded on April 27, 2011 for gene editing services to generate customized cell and animal models, including knockout mouse models, reporter cell lines, and stem cell models with disease-associated...
This firm fixed-price purchase order was awarded by the National Institute of Child Health and Human Development (NICHD), part of the Department of Health and Human Services, to Applied Stemcell, Inc. for the generation of a conditional knockout mouse model using CRISPR/Cas9 gene editing technology. The award amount is $26,065.00, and the period of performance runs through July 19, 2021. The contract does not have a set-aside designation. Applied Stemcell is a minority-owned, woman-owned small...
This is a firm fixed-price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Applied Stemcell, Inc. The contract is for $12,450.00 and has a completion date of September 24, 2019. Applied Stemcell, Inc. is a minority-owned, woman-owned small business that provides gene editing services and GMP iPSC manufacturing to support cell-based research projects. Through past federal contract awards, the company has provided gene editing...
This is a Firm Fixed Price Purchase Order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Applied Stemcell, Inc. - doing business as Applied Stemcell Inc. - a minority-owned, woman-owned small business. The $12,080.00 contract is for services to provide knockout cell line services. This contract award is not set aside. Based on the agency and the services provided, this contract likely supports NICHD's research on child health and...
This federal contract award to Applied Stemcell, Inc. (a minority owned, woman owned small business) was made by the National Institute of Child Health and Human Development (NICHD), a civilian agency, on August 11, 2019. The $12,639.00 firm fixed price purchase order is for "KNOCKOUT CELL CLONE RASD1" services. Through this award, Applied Stemcell has provided gene editing services to generate customized cell and animal models, including knockout mouse models, reporter cell lines, and...
This firm fixed-price purchase order was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency under the Department of Health and Human Services, to Applied Stemcell, Inc., a minority-owned and woman-owned small business. The $24,115 contract is for NIDDK's F1 Breeding and Genotyping project, which involves gene editing services and GMP iPSC manufacturing to support cell-based research. Applied Stemcell has provided similar services to other...
This is a $14,999.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Applied Stemcell, Inc. The contract is for applied gene editing services to support cell-based research projects, including the generation of customized cell and animal models. Applied Stemcell is a minority-owned, woman-owned small business that has previously received federal research grants and contract awards...
The National Institute of Child Health and Human Development (NICHD), a civilian agency, awarded a firm fixed-price purchase order to Applied Stemcell, Inc. - a minority-owned, woman-owned small business - for $20,150.00 to provide cell line evaluation services. The contract has a completion date of September 11, 2019. Applied Stemcell has previously provided gene editing services to various NIH institutes through federal contracts and grants, supporting the development of customized cell and...
This is a $13,760 firm fixed price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Applied Stemcell, Inc. for the generation of point mutation induced pluripotent stem (iPS) or embryonic stem (ES) cell lines using CRISPR/Cas9 gene editing technology. The work is to be performed in Bethesda, MD and has a completion date of March 31, 2022. Applied Stemcell, Inc. is a minority-owned, woman-owned small business that provides...
This is a $122,400.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business. The contract is for molecular and pathophysiological studies of Parkinson's disease dementia and does not have a set-aside designation. Applied Stemcell, Inc. provides gene editing services and good manufacturing practice (GMP) induced...